Boehringer Ingelheim’s experimental weekly injection, survodutide, demonstrates significant weight loss and better blood sugar control in a phase 3 trial, offering a potential new approach to tackling obesity and diabetes, though concerns around tolerability remain.
An experimental weekly injection from Boehringer Ingelheim helped adults with obesity or overweight and type 2 diabetes lose as much as 13.1% of their body weight over 76 weeks, according to results published in The New England Journal of Medicine and presented at the European Association for the Study of Diabetes annual meeting. The placebo group lost 3.1% over the same period, placing survodutide among the more potent obesity drugs now in late-stage development, although it remains unapproved and unavailable outside trials.
The phase 3 SYNCHRONIZE-2 study enrolled 755 adults and tested weekly doses of 3.6 mg and 6.0 mg. Alongside the weight-loss effect, researchers reported better blood sugar control, with average HbA1c falling by as much as 1.21 percentage points from a starting level of 7.4%. Nearly 30% of people taking survodutide reached an HbA1c level below 5.7%, the normal range, compared with 4.0% on placebo. Waist circumference also fell by more than 11 centimetres in the treatment groups.
The trial adds to a broader wave of research into weight-loss medicines that also affect metabolism. A separate New England Journal of Medicine report on CagriSema, a combination of cagrilintide and semaglutide, showed that another injectable approach can also deliver substantial weight loss in people with type 2 diabetes. And in a different obesity study, setmelanotide produced meaningful weight loss in patients with acquired hypothalamic obesity, underlining how rapidly the field is expanding beyond the familiar GLP-1 class.
Survodutide works differently from better-known treatments such as semaglutide and tirzepatide because it targets two receptors: GLP-1 and glucagon. GLP-1 helps reduce appetite and slows stomach emptying, while glucagon can increase energy expenditure and affect the liver. That dual action is also why Boehringer is studying the drug in metabolic dysfunction-associated steatohepatitis, or MASH, where a phase 2 trial published in The New England Journal of Medicine found encouraging liver-related benefits. Researchers have not yet shown whether adding glucagon translates into better long-term outcomes than existing drugs.
The clearest concern remains tolerability. About 18% of participants stopped survodutide because of stomach-related side effects, compared with 1.2% on placebo, with nausea, vomiting, diarrhoea and constipation driving most dropouts. The 13.1% weight-loss figure reflects an efficacy analysis that assumes patients stayed on treatment, so real-world results may be less dramatic. Even so, investigators said the findings support the idea that treating obesity can improve wider metabolic health. The drug is still being tested, no FDA filing date has been announced, and current results do not change present-day diabetes care.
Disclaimer: This content is for informational purposes only and is not intended to be a substitute for professional medical judgment, advice, diagnosis, or treatment.
